Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
Transl Cancer Res
.
2019 Mar;8(Suppl 2):S103-S105.
doi: 10.21037/tcr.2018.11.06.
Authors
Andrea Bianco
1
,
Susan F M Campbell
1
Affiliation
1
Department of Translational Medical Sciences, University of Campania "L Vanvitelli", Napoli, Italy.
PMID:
35117074
PMCID:
PMC8797422
DOI:
10.21037/tcr.2018.11.06
No abstract available
Publication types
Editorial
Comment